RGNCY0129 (Compound 4h MARK4 inhibitor)
Compound 4h is a novel selective MARK4 inhibitor with binding verified by molecular docking and flourescence biding assays. MARK4 is a therapeutic target for cancer drug development due to its involvement in microtubule dynamics, cell cycle regulation and cancer progression. Compound 4h exhibited apoptotic, antiproliferative and antioxidant activity in cell-based assays. 4h has a K value of 3.6 x 103 M-1 for human serum albumin demonstrating its remarkable transportation and delivery properties to the target site through the blood.
Systematic Name: (Z)-(5-nitro-1H-imidazol-1-yl)(2-(trifluoromethyl)phenyl)methanone oxime
Mol Wt: 300.20
Tags: Apoptosis, small molecule, RGNCY-0129, 4h, compound 4h, MARK4